posted
KKUR: Who would have thought that tis baby would come in from behind today. Are we looking at another "BONU" or "HGSI" in the making ? This one opened at 0.0009 this morning, traded in red until about 2:30 P.M. (Central Standard Time) to explode at a change of 277.78% due to the below news announement.
ChromoCure, Inc. Announces Development of New Generation of High-Speed Chromosomal Scanners for Cancer DetectionFont size: A | A | A2:28 PM ET 8/31/09 | Market Wire ChromoCure, Inc. (PINKSHEETS: KKUR) released today its development plan for its next generation of chromosomal scanners. The new system has been given the name "CS300" as the next iteration of its current CS200 Chromosomal Scanner design.
The new CS300 will retain all of the features of CS200 with these important additions:
-- On-Slide direct application of DNA-probes using robotic micro-applicator
-- User-selectable chromosome probe types -- one probe or multiple simultaneous probes
-- Full integration of de-paraffinization and cellular disaggregation of tissue samples for non-cytology originated diagnostics
The CS300's design parameters introduce significant throughput improvements allowing the CS300 to process hundreds of patient scans per day, per machine. The company is not aware of any similar automated high-speed chromosomal scanner in the marketplace.
The company has executed a joint research and development agreement with one of its equipment partners to complete the CS300 in preparation for a nationwide marketing plan.
The Company is completing its consolidated GAAP financials statements for the year 2007 through 2009. These financials are published pursuant to paragraphs (a)(5)(i) to (xiv), inclusive, and paragraph (a)(5)(xvi) of Rule 240.15c2-11 and the OTC Disclosure Guidelines and will be timely published as part of the Company's ongoing disclosure practices.
The Company anticipates updating stockholders on the following items:
-- Announcement of joint research and development agreement
-- Initial scanner installations with diagnostic labs
-- Elimination of significant long-term liabilities and removal from the Balance Sheet
-- Acquisition of intellectual property, technology, and subsequent patent filings
-- Additional appointment to the Company's Advisory and Business Development Boards
-- Acquisition of profitable pathology labs to expand the company's operations
-- Research and Development agreements with industry partners
-- Regular updates and commentary on the Company's technology
About ChromoCure
ChromoCure develops and provides proprietary cancer detection systems. The Company owns its technology and provides its systems on a revenue sharing basis. The Company's systems measure the unique genomic characteristic found in 100% of all cancers and never found in normal cells. The Company believes its technology has an effective accuracy of 100% for all cancers at all stages. The Company believes its technology vastly superior to anything in existence and that it will become the undisputed gold standard for cancer detection worldwide.
The Company's technology and understanding of cancer also suggest non-toxic and non-invasive approaches to cancer therapy and cure research. The Company will release progress reports on these initiatives from time to time.
Safe-Harbor Statement
This press release contains statements (such as projections regarding future performance) that are forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those projected as a result of certain risks and uncertainties. The company's filings contain various RISK FACTORS (and are incorporated herein by reference) and should be read before any investment decision.
Investor Relations: Contact: ChromoCure, Inc. info*chromocure.com Tel 1.775.636.6548
posted
The company is good in communicating with investors and releases news so that investors may know what is going on...good or bad.
Posts: 602 | From: Minneapolis | Registered: Jul 2009
| IP: Logged |
posted
Please just do not take my words for what it's worth. Always do your own research before you purchase any share and use caution when purchasing.
Posts: 602 | From: Minneapolis | Registered: Jul 2009
| IP: Logged |
posted
KKUR: Who would have thought that tis baby would come in from behind today. Are we looking at another "BONU" or "HGSI" in the making ? This one opened at 0.0009 this morning, traded in red until about 2:30 P.M. (Central Standard Time) to explode at a change of 277.78% due to the below news announement. Do your own research before any purchase as in "always".
Posts: 602 | From: Minneapolis | Registered: Jul 2009
| IP: Logged |
posted
Who would of thought it! I wish i would have seen it before the run. I keep thinking Bonu will crash, but it just keeps going up. Will look into this one. It sounds pretty good.
posted
Yes indeed, Dagny, KKUR looks great given it's bacground. How I wish I got in at a lower price than 0.0029. I would have gotten more shares and so far profit. Bonu will continue to be strong and resiliant. The Swine Flu thing is a serious thing in our lives you know.
Posts: 602 | From: Minneapolis | Registered: Jul 2009
| IP: Logged |
posted
Hot-Pepper: Think there'll be a pullback on KKUR in the opening 1/2 hour??? YEAH - RIGHT - like BONU did today! It puuled back OK - like a friggin' SLINGSHOT to the Stratosphere!! LOL (I just have to be a happy little pig on this one - from the $3K I made last week, but the "What COULD of been and ALMOST was" - like up $15K; is driving me NUTS....Would have wiped out all my losses over the past 6 years and even put me positive a little)....
I still can't BELIEVE the little stock that was under 40 cents like a week ago went up $1.21 today is now BIG TIME! Hey - maybe I should by in at $5.00 tomorrow?? LOL - But NOT funny. :-(
My portfolio dropped about $1,600 in the last half hour today. Even my portfolio couldn't take watching BONU!!
Posts: 2793 | From: Coral Springs, FL, USA | Registered: Aug 2003
| IP: Logged |
posted
Love the Market, I do not think so ! imo. There are lots of profit takers waiting to send it down, at a time and you may not be able to predict when unless you see the bid comming before execution. When that happens it will take a dip, but once it dips, take advantage of that and and get in or buy more for the afternoon run. I would say REMAIN CALM, know when to sell and be ready to get in when the right time occurs. "Remember, a profit is a profit and it's better than a loss.
With regards to BONU, again, nobody knows if the stock will hit $5.00 tomorrow. If it does, I will be one of the happy ones. But at the rate it is going, it could hit $5.00 before the week is over...imo. Again, remain calm.
Posts: 602 | From: Minneapolis | Registered: Jul 2009
| IP: Logged |
posted
I'll try and get in this in the morning. WORSTI can do is lose some BONE profits..... Then again - maybe I should hope BONU ... NAAAAAAA up WAY to far already! (YEAH - RIGHT) If I BUY again - it WILL DROP! My luck as a trader!! ENJOY! So I won't buy BONU again and you hold - and send me half - 'cuz you'll do GREAT!
Heck - BONU could hit $15 by the end of the week...on hype.... OR be back to .60 if that stuff about it being no different than Lysol is true. But WHAT a MAGNIFICENT RIDE for those who stayed in - either because they were lucky and DIDN'T put in sells like I did - or we're hoping for the ultimate magic carpet! I had this happen with UVCL like 6 years ago when I first started - went from .01 to .17 in 4 days - and I NEVER SOLD!!!! (Because it had been at $1.25 the year before). DUMB. I still have 350,000 shares of that one (now like .0008). I made some good money trading it - but lost WAYYYY more. But the magnitude of these BONU numbers make it look SOOooooo HOT ! Like the "super pretty Kardashian - NOT Kim - or a blonde Heffner Bunny! (Sorry Ladies)!
Posts: 2793 | From: Coral Springs, FL, USA | Registered: Aug 2003
| IP: Logged |
posted
ChromoCure, Inc. Announces Technology and Intellectual Property Assets Acquisition Adding $1,500,000 to Assets and EquityFont size: A | A | A11:58 AM ET 9/3/09 | Market Wire ChromoCure, Inc. (PINKSHEETS: KKUR) announced today it executed a Technology Purchase and Transfer Agreement for $1,500,000, payable in Preferred Stock, wherein the Company receives full title and transfer of all rights, trademarks, intellectual property, protocols, patent disclosures, chromosomal scanner equipment, all proprietary analysis algorithms, mathematical analysis procedures, prior testing data with cancer clinics, cell preparation procedures, and all new hardware designs currently in development related to cancer detection and chromosomal scanning, enumeration, and analysis.
The transaction structure was specifically designed to avoid incurring long-term liabilities in the form of shareholder equity-reducing debt. Instead, the acquisition adds assets and equity and builds shareholder equity.
As previously disclosed, the transition of the company to its new business plan and operations is an essential component of the company's 2009 plan for operations. The Company executed this portion of it plan of operations as previously planned to be immediately subsequent to completion of financial disclosures and filings.
The company recently completed its disclosures and financials as part of this transition plan and succeeded in the removal of the "Caveat Emptor" status associated with the company's prior operations.
The remainder of the Company's plan of operations for 2009 will continue to be executed and investors updated accordingly.
Updates will be timely published on the following:
View data-- Announcement of joint research and development agreement. -- Initial scanner installations with diagnostic labs. -- Elimination of significant long-term liabilities and removal from the Balance Sheet. -- Additional appointments to the Company's Advisory Boards. -- Acquisition of profitable labs to expand the company's operations. -- Release of technology and industry White Papers.
-- Announcement of joint research and development agreement. -- Initial scanner installations with diagnostic labs. -- Elimination of significant long-term liabilities and removal from the Balance Sheet. -- Additional appointments to the Company's Advisory Boards. -- Acquisition of profitable labs to expand the company's operations. -- Release of technology and industry White Papers.
About ChromoCure
ChromoCure develops and provides proprietary cancer detection systems. The Company owns its technology and provides its systems on a revenue sharing basis. The Company's systems measure the unique genomic characteristic found in 100% of all cancers and never found in normal cells. The Company believes its technology has an effective accuracy of 100% for all cancers at all stages. The Company believes its technology superior and will become the gold standard for cancer detection worldwide.
The Company's technology and understanding of cancer also suggest non-toxic and non-invasive approaches to cancer therapy and cure research. The Company will release progress reports on these initiatives from time to time.
Safe-Harbor Statement
This release contains statements or projections regarding future performance that are forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those projected as a result of certain risks and uncertainties. The company's filings contain various RISK FACTORS (and are incorporated herein by reference) and should be read before any investment decision.
Investor Relations: Contact: ChromoCure, Inc. info*chromocure.com Tel 1.775.636.6548
posted
ChromoCure, Inc. Announces Elimination of $800,000 of Debt WithCyberhand Asset Sale
Sep 9, 2009 09:30:10 (ET)
VANCOUVER, BC, Sep 09, 2009 (MARKETWIRE via COMTEX) -- ChromoCure, Inc. (PINKSHEETS: KKUR) announced today it executed an Asset Purchase Agreement with certain secured creditors owning $800,000 of company debt. The debt is secured by all of the assets of the prior "Cyberhand" operations. The Company and the creditors have agreed to exchange these assets for complete elimination of the debt.
As previously announced, it is the intention of the creditors to establish new operations with the Cyberhand assets and distribute stock in the new company, pro rata, to all prior stockholders of Cyberhand. ChromoCure has agreed to supply the new company with all shareholder information for the planned stock distribution.
The transaction structure was specifically designed to eliminate long-term liabilities. The elimination of this long-term liability releases the company from its secured debt obligation and improves shareholder equity.
Elimination of this Note removes substantially all of the company's long-term liabilities and leaves the company comparatively debt-free.
Updates will be timely published on the following:
-- Announcement of joint research and development agreement -- Initial scanner installations with diagnostic labs -- Elimination of significant long-term liabilities and removal from the Balance Sheet -- Additional appointments to the Company's Advisory Boards -- Acquisition of profitable labs to expand the company's operations -- Release of technology and industry White Papers
About ChromoCure
ChromoCure develops and provides proprietary cancer detection systems. The Company owns its technology and provides its systems on a revenue sharing basis. The Company's systems measure the unique genomic characteristic found in 100% of all cancers and never found in normal cells. The Company believes its technology has an effective accuracy of 100% for all cancers at all stages. The Company believes its technology is superior and will become the gold standard for cancer detection worldwide.
The Company's technology and understanding of cancer also suggest non-toxic and non-invasive approaches to cancer therapy and cure research. The Company will release progress reports on these initiatives from time to time.
Safe-Harbor Statement
This release contains statements or projections regarding future performance that are forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those projected as a result of certain risks and uncertainties. The company's filings contain various RISK FACTORS (and are incorporated herein by reference) and should be read before any investment decision.
Investor Relations: Contact: ChromoCure, Inc. info*chromocure.com Tel 1.775.636.6548
posted
ChromoCure KKUR Was this just a pump on this co? I looks like it is going to the bottom.
Posts: 49 | From: Texas | Registered: Jul 2009
| IP: Logged |
posted
ChromoCure, Inc. makes key appointment to Medical Advisory Board and Business Development TeamFont size: A | A | A9:30 AM ET 9/22/09 | PR Newswire ChromoCure, Inc. (PINKSHEETS: KKUR) announced today it has appointed Mikhail Kantius, MD to its Advisory Board and business development team. Dr. Kantius will assist the company in forming strategic alliances as well as promote the company's technology and service to pathology labs throughout the Northeast United States.
About Mikhail Kantius, M.D., F.C.A.P., Advisory Board and Lead Pathologist. Trained and Board Certified Surgical Pathologist/Dermatopathologist. He brings a 20 year career of experience as Medical Director/ Administrator/Surgical Pathologist and Dermatopathologist in a privately owned commercial Pathology Laboratory. His early research interests were involved in Tissue culture and Cytogenetics. He holds unrestricted licenses to practice in state of NY, NJ, Florida and Maine.
View data Shareholders will soon receive updates on the following:
- Announcement of joint research and development agreement - Initial scanner installations with diagnostic labs - Elimination of significant long-term liabilities and removal from the Balance Sheet. - Acquisition of profitable diagnostic labs to expand the company's operations - Release of technology and industry White Papers.
Shareholders will soon receive updates on the following: - Announcement of joint research and development agreement - Initial scanner installations with diagnostic labs - Elimination of significant long-term liabilities and removal from the Balance Sheet. - Acquisition of profitable diagnostic labs to expand the company's operations - Release of technology and industry White Papers.
About ChromoCure
ChromoCure develops and provides proprietary cancer detection systems. The Company owns its technology and provides its systems on a revenue sharing basis. The Company's systems measure the unique genomic characteristic found in 100% of all cancers and never found in normal cells. The Company believes its technology has an effective accuracy of 100% for all cancers at all stages. The Company believes its technology superior and will become the gold standard for cancer detection worldwide.
The Company's technology and understanding of cancer also suggest non-toxic and non-invasive approaches to cancer therapy and cure research. The Company will release progress reports on these initiatives from time to time.
Safe-Harbor Statement
This release contains statements or projections regarding future performance that are forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those projected as a result of certain risks and uncertainties. The company's filings contain various RISK FACTORS (and are incorporated herein by reference) and should be read before any investment decision.
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
